AUTORIZZAZIONE ALLO SVOLGIMENTO PRESSO LA U.O.C. ONCOLOGIA MEDICA 2 DELL’ISTITUTO REGINA ELENA DELLA SPERIMENTAZIONE “STUDIO RANDOMIZZATO DI FASE 3 SU METX849 IN ASSOCIAZIONE CON CETUXIMAB RISPETTO ALLA CHEMIOTERAPIA IN PAZIENTI CON CANCRO COLORETTALE AVANZATO CON MUTAZIONE G12C DEL KRAS E PROGRESSIONE DELLA MALATTIA DURANTE O DOPO TERAPIA STANDARD DI PRIMA LINEA” E APPROVAZIONE ACCORDO CON MIRATI THERAPEUTICS, Inc. Protocollo n. 849-010 EudraCT n. 2020-004048-27 RESPONSABILE: Dr. Federico Cappuzzo R.S. 1595/21
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.